2008-10-07 17:03:01 -

- Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that CEO, Jim Holmes, has been featured in an interview on www.stockbully.com. In the interview, Mr. Holmes discussed the recent formation of First Warning Systems, Inc., as well as advances in the development of the company's patented First Warning System, a technology designed to assist in the early, non-invasive, non-radiation, non-compression

detection of breast cancer.

Stockbully.com gives attention to emerging growth companies that seek more exposure in the investment community. Stockbully.com is a multimedia investor relations source that seeks out promising and mostly undiscovered companies in the market place and enables their clients to utilize multimedia marketing to gain exposure via the information highway.

"We are excited about the creation of our First Warning Systems, Inc. subsidiary and the focus commercializing the potentially lifesaving technology. With the creation of First Warning Systems, Inc., we can focus on the process of searching for and validating a number of potential strategic partners," stated Lifeline Biotechnologies, Inc. President and CEO Jim Holmes.

About Stockbully.com

Stockbully.com differentiates itself from traditional investor relations businesses in that it strives to take a long-term approach. It nurtures and supports promising emerging companies with the aim of growing and appreciating in value. Through exposure on the Internet, Stockbully.com enables its clients to secure a place in their respective sector. Clients with limited financial means can utilize multimedia marketing via the Internet to gain a competitive edge. For more information, please visit www.stockbully.com/.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System(TM), which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System(TM), the completion of clinical trials and FDA pre-marketing clearance. Additional information can be found on the Company's website at: www.lbti.com.

Lifeline competes in the money markets for funds to support the development and commercialization of its products. The cost of funds, for early stage companies like Lifeline, is expensive and the terms have been, and may continue to be, dilutive.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

e-media Direct, Inc.
Investor Relations, 866-284-2835
info@e-mediadirect.com